Mindset Pharma is a leader in developing next-generation psychedelic medicines to treat neurological and psychiatric disorders.

ABOUT US

Company Overview

Mindset Pharma is a Toronto-based drug discovery business focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders.

Play Video

Pipeline

Mindset has developed 4 families of novel, next-generation psychedelics with differentiated characteristics and improved safety profiles. Read More

Click to enlarge

Family

Family 1 / MSP-1014: Psilocybin-like conjugate.

Family 2: High-potency, short-acting, psilocybin-like.

Family 3: Low-potency, long-duration for micro-dosing

Family 4: DMT/ 5-MeO-DMT-inspired compounds

Lead Identification

Lead Optimization

IND-Enabling

Clinical
Phase 1

Recent News

May 12, 2022
Mindset Pharma Progresses Plans for Clinical Trials of its Advanced Pre-Clinical Psychedelic, MSP-1014
May 04, 2022
Mindset Pharma to Participate in Upcoming Conferences in May 2022
Apr 19, 2022
Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds
Apr 05, 2022
Mindset Pharma to Participate in Upcoming Conferences in April 2022
Subscribe for latest news